Market closedNon-fractional
Eagle Pharmaceuticals/EGRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Eagle Pharmaceuticals
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Ticker
EGRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Woodcliff Lake, United States
Employees
134
Website
www.eagleus.com
EGRX Metrics
BasicAdvanced
$71M
Market cap
6.03
P/E ratio
$0.91
EPS
0.43
Beta
-
Dividend rate
Price and volume
Market cap
$71M
Beta
0.43
Financial strength
Current ratio
2.161
Quick ratio
1.506
Long term debt to equity
26.247
Total debt to equity
29.539
Interest coverage (TTM)
6.85%
Management effectiveness
Return on assets (TTM)
6.63%
Return on equity (TTM)
4.88%
Valuation
Price to earnings (TTM)
6.033
Price to revenue (TTM)
0.279
Price to book
0.29
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-7.662
Growth
Revenue change (TTM)
-5.38%
Earnings per share change (TTM)
-48.44%
3-year revenue growth
13.24%
3-year earnings per share growth
39.39%
What the Analysts think about EGRX
Analyst Ratings
Majority rating from 2 analysts.
EGRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$65M
-2.56%
Net income
$5.1M
-10.53%
Profit margin
7.89%
-8.15%
EGRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 22
Q4 22
Q1 23
Q2 23
Actual
$1.12
$1.10
$1.26
-
Expected
$0.91
$0.83
$1.05
$1.05
Surprise
23.53%
32.53%
20.00%
-
EGRX News
AllArticlesVideos
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewsWire·1 month ago
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
GlobeNewsWire·3 months ago
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eagle Pharmaceuticals stock?
Eagle Pharmaceuticals (EGRX) has a market cap of $71M as of July 06, 2024.
What is the P/E ratio for Eagle Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eagle Pharmaceuticals (EGRX) stock is 6.03 as of July 06, 2024.
Does Eagle Pharmaceuticals stock pay dividends?
No, Eagle Pharmaceuticals (EGRX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Eagle Pharmaceuticals dividend payment date?
Eagle Pharmaceuticals (EGRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Eagle Pharmaceuticals?
Eagle Pharmaceuticals (EGRX) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Eagle Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.